Skip to content

Effects of Physiotherapy in Children With Hirschsprung's Disease

Investigation of Effects of Physiotherapy in Children With Hirschsprung's Disease

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07156981
Enrollment
20
Registered
2025-09-05
Start date
2025-09-30
Completion date
2026-01-30
Last updated
2025-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hirschsprung Disease

Brief summary

The aim of our study is to investigate the effects of physiotherapy in children with Hirschsprung's disease who have bowel symptoms after surgery.

Detailed description

Hirschsprung's disease is a developmental disorder of the enteric nervous system characterized by the absence of ganglion cells in the distal intestine, resulting in functional intestinal obstruction. The treatment applied after diagnosis is surgical. Although individuals with a history of surgery due to Hirschsprung's disease generally have normal bowel and urinary function, it has been reported that they have a higher prevalence of fecal incontinence and constipation and a lower quality of life related to the gastrointestinal system. However, there are few studies evaluating the use of physiotherapy in the management of postoperative bowel symptoms in children with Hirschsprung's disease.

Interventions

BEHAVIORALPhysiotherapy

The treatment program will include patient education, lifestyle recommendations, breathing exercises, pelvic floor muscle training, and stabilization exercises. The treatment program will last for a total of 8 weeks.

Sponsors

Ankara Yildirim Beyazıt University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Children aged 5-18 who have undergone surgery for Hirschsprung's disease and have intestinal symptoms, and who come for routine check-ups. * Volunteering to participate in the study

Exclusion criteria

* Presence of a congenital and/or chronic disease * Those with missing assessment parameters * Having a history of any additional orthopedic, neurological or psychiatric disease that will affect the evaluation parameters * Loss of sensation * Mental retardation

Design outcomes

Primary

MeasureTime frameDescription
Bowel functionbefore and after treatment (8-week change)Bowel function will be evaluated with a bowel diary. They will be asked to keep a bowel diary for 1 week, including the number and type of daily stools and the number of incontinent stools.

Secondary

MeasureTime frameDescription
Constipationbefore and after treatment (8-week change)Children's constipation will be evaluated with the Rome IV criteria. These criteria include; two or less defecation per week, fecal incontinence at least once a week, history of holding/ delaying the large toilet, painful and difficult bowel movements, presence of large feces in the rectum, presence of a history of large feces that can block the toilet. An increase in the number of symptoms indicates the severity of constipation.
Pelvic floor muscle functionbefore and after treatment (8-week change)Pelvic floor muscle function will be evaluated with palpation form anus. The presence of correct contraction and relaxation of the pelvic floor muscle will be determined.
Life qualitybefore and after treatment (8-week change)Life quality will be assessed with the Pediatric Quality of Life Inventory (PedsQL). The PedsQL consists of 23 items. It are scored between 0-100. The higher the total score of the life quality, the better health-related life quality is perceived.
Perception of improvementafter treatment (8-week change)Subjective perception of improvement will be assessed as -1 (worse), 0 (no change) and 1 (better).
Compliance with recommendationsafter treatment (8-week change)Compliance with post-treatment recommendations will be assessed with the Visual Analog Scale (VAS). The VAS is a horizontal line with 0 at one end as never compliance and '10' at the other end as always compliance.

Contacts

Primary ContactSeyda Toprak Celenay
sydtoprak@hotmail.com+90 312 906 1000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026